Koru Medical upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler analyst Jason Bednar upgraded Koru Medical Systems to Overweight from Neutral with a price target of $3.50, up from $3. The company reported Q3 revenue that beat consensus for the seventh consecutive time, showing sustainability of 15% growth, Bednar tells investors in a research note. The analyst says this increases his confidence in Koru’s 2023 and beyond outlook. The stock’s valuation has "turned increasingly attractive over the last few months," with current levels representing a "compelling opportunity for small-cap investors," contends Bednar.